Hybridon

Hybridon, Inc (Amex: HBY) was a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of novel therapeutics and diagnostics using synthetic DNA, that merged with Idera Pharmaceuticals in 2004.

According to a U.S. Securities and Exchange Commission filing of May 4, 1999 Hybridon had investors with 5% or more ownership including: